Search

"Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: Three-year results from the randomized SCHEDULE study" (AJT 2016)

Originally aired on February 18, 2016 • 11:00 am EST • Hosted by the Thoracic and Critical Care Community of Practice

Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: Three-year results from the randomized SCHEDULE study (January 2016)
(A subscription to AJT is required to view the full article, AST is not permitted to distribute the full text of the article.)

Authors:
Satish Arora, MD, PhD • Oslo University Hospital Rikshospitalet
Arne Kristian Andreassen, MD, PhD • Oslo University Hospital Rikshospitalet
Einar Gude, MD, PhD • Oslo University Hospital Rikshospitalet
Lars Gullestad , MD, PhD • Oslo University Hospital Rikshospitalet

Facilitator:
Jon Kobashigawa, MD • Cedars-Sinai Heart Institute

Watch Video

AST/AJT Journal Club

See all Journal Clubs

Donate

Donate

Donate

to the American Society of Transplantation

Career Center

Career Center

Career Center

Connecting Transplantation Talent with Opportunities

Patient Education

Patient Education

Educating the Community

The AST initiative, Power2Save, has great resources for patients and patient families.

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.